138 results about "Cell Maturation" patented technology

The present invention provides compositions and methods for inducing maturation of immature dendritic cells (DC) and for priming those cells for inducing a type 1 immune response. The present invention also provides dendritic cell populations useful for activating and for preparing T cells polarized towards production of type 1 cytokines and / or a type 1 response. Similarly, activated, polarized T cell populations, and methods of making the same are provided.

The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.

The present invention concerns RPE cells obtainable by directed differentiation from stem cell, particularly, human stem cells. It has been specifically found that culturing stem cells in the presence of one or more member of the TGFβ superfamily, such as Activin A) induced directed differentiation into mature and functional RPE cells. This was evidenced by the expression of markers specific to mature RPE cells, including MiTF-A, RPE65 or Bestrophin). In accordance with one particular embodiment, the cells are a priori cultured with nicotinamide (NA) which was found to augment the cells' response to the inductive effect of the one or more member of the TGFβ superfamily. The invention also provides methods of performing the directed differentiation, as well as methods for use of the resulting RPE cells.

Disclosed herein are methods, compositions, kits, and agents useful for inducing β cell maturation, and isolated populations of SC-β cells for use in various applications, such as cell therapy.

The present invention relates to a method of culturing peripheral lymphoid organ cells on a three-dimensional scaffolding which is covered or surrounded with culture medium, under conditions effective to generate and maintain mature and functional lymphoid cells, where the three-dimensional scaffolding allows cells in the culture medium to have cell to cell contact in three dimensions. The present invention also provides methods of screening for vaccine candidates for efficacy in eliciting an immune response, identifying genes or proteins which are related to peripheral lymphoid organ cell formation or function, screening for drugs effecting peripheral lymphoid organ cell maturation, treating a patient for a disease condition using antigen-specific lymphoid cells, and effecting gene expression of peripheral lymphoid organ cells.

Disclosed herein are methods, compositions, kits, and agents useful for inducing β cell maturation, and isolated populations of SC-β cells for use in various applications, such as cell therapy.

The invention relates to a chimeric antigen receptor (CAR) and application thereof. The CAR comprises BCMA (B-cell maturation antigen) binding structural domains, transmembrane structural domains, oneor a plurality of co-simulation structural domains and intracellular signal transduction structural domains. The BCMA binding structural domains comprise heavy chain complementary determining regionsHCDR 1-3, and amino acid sequences of the HCDR 1-3 are sequentially shown as SEQ ID NO:1-3.

Reference control compositions and the method of use are disclosed for measurement of nucleated red blood cells, which includes one set of synthetic spherical particles having a mean particle diameter ranging from 6.2 μm to 6.8 μm and a refractive index from 1.58 to 1.62 monodispersed in an aqueous suspension medium. The synthetic spherical particles have optical properties simulating optical properties of nucleated red blood cells as measured by optical measurements. The reference control composition can further include a second set of the synthetic spherical particles having optical properties simulating optical properties of white blood cells. Further disclosed is a reference control system which includes a series of reference control compositions, each having an amount of one type of synthetic spherical particles which have optical properties simulating the optical properties of nucleated red blood cells having a specific cell maturity.

Provided are chimeric antigen receptors (CARs) having antigen specificity for B-cell Maturation Antigen (BCMA). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.

The present invention relates to chimeric antigen receptor targeting BCMA(J22.9), and uses thereof, and particularly provides a polynucleotide sequence, which is selected from (1) a polynucleotide sequence containing the coding sequence of an anti-BCMA single chain antibody, the coding sequence of a human CD8 alpha hinge region, the coding sequence of a human CD8 transmembrane region, and the coding sequence of a human 41BB intracellular region, wherein the coding sequences are sequentially linked, and (2) a sequence complementary to the polynucleotide sequence (1). The present invention further provides a related fusion protein, a vector containing the coding sequence, and uses of the fusion protein, the coding sequences, and the vector.

There is provided a cell image acquisition device, method, and a non-transitory computer readable recording medium recorded with a program to reduce the amount of data to be processed and stored by limiting a target region in a colony region when imaging a cell colony. There are included: a maturity information acquisition unit 22 that acquires information regarding the maturity of cells being cultured; a colony region specifying unit 21 that acquires a cell image by imaging the cells at a first magnification and specifies a colony region of the cells in the cell image; a target region determination unit 23 that determines a target region in the colony region of the cells based on the information regarding the maturity; and a high magnification image acquisition unit 24 that acquires a high magnification image by imaging the target region at a second magnification that is higher than the first magnification.

B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides BCMA-specific chimeric antigen receptors and cells expressing such chimeric antigen receptors. In certain embodiments, engineered cells expressing the chimeric antigen receptors of the present invention are capable of inhibiting the growth of tumors expressing BCMA. The engineered cells of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desired and / or therapeutically beneficial. For example, engineered cells expressing the BCMA-specific chimeric antigen receptors of the invention are useful for the treatment of various cancers, including multiple myeloma.

Polypeptides and proteins that specifically bind to and immunologically recognize B-Cell Maturation Antigen (BCMA) are disclosed. Chimeric antigen receptors (CARs), anti-BCMA binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer and methods of treating or preventing cancer are also disclosed.

The invention relates to the medical biology field, in particular to an anti-BCMA (B-cell maturation antigen) antibody, an antigen binding fragment thereof, and a chimeric antigen receptor (CAR) containing the anti-BCMA antibody. The invention also relates to a nucleic acid molecule capable of encoding the CAR, a modified immune cell containing the CAR, and a method for preparing the modified immune cell. The invention also relates to the purposes of the CARs and the modified immune cell for preventing and / or treating B-cell related illness states (such as B-cell related and plasma cell related malignant tumors and autoimmune diseases) and a method for preventing and / or treating the B-cell related illness states.

The invention discloses a method for differentiating induced pluripotent stem cells (iPSC) into mesenchymal stem cells (MSC). The method includes the steps that the induced pluripotent stem cells formed through induction are dissociated into single cells; the single cells are cultivated in a cell plate coated with I type collagen through an iPSC medium and one differential medium including platelet-derived growth factors, and then cultivated in another differential medium to obtain MSC-like cells; and finally, the MSC-like cells are maturated in an MSC medium to obtain the MSC. According to the induction approach, the iPSC is directly differentiated into the MSC, and the method has the beneficial effects of being short in period, high in efficiency, safe, stable and the like.

Human induced pluripotent stem cell (iPSC) technology combined with a hollow fiber based bioartificial liver (BAL) device can benefit patients with liver failure. Defined iPSC lines can provide unlimited supply of functional hepatocytes by developing iPSC derived hepatocytes (iHeps). Disclosed herein is a protocol for deriving metabolically active hepatocytes from iPSCs. In some embodiments, iHeps were cultured on microcarrier beads in spinner flasks. Subsequently, the iHep-microcarrier complexes were loaded into the extracapillary space of a hollow fiber bioreactor cartridge and cultured using closed circuit continuous flow system. The iHeps secreted human albumin, prothrombin and apolipoprotein B into the hollow fiber intracapillary space media which indicated the maintenance of plasma protein secretory function. In addition, the continuous flow system improved the maturation of iHeps. Thus, the iPSC hepatocytes in the bioartificial liver device maintained the secretory function and exhibited cell maturation.

The invention belongs to the technical field of genetic engineering, and specifically relates to an anti-BCMA (B-cell Maturation Antigen) humanized single-chain antibody and application thereof. The amino acid sequence of the anti-BCMA humanized single-chain antibody is as show in SEQ ID NO: 19 or 20 or 21 or 22 or 23. The anti-BCMA humanized single-chain antibody is formed by sequentially connecting a light chain variable region, a Linker and a heavy chain variable region; the humanization degree is high; the immunogenicity of CAR (Chimeric Antigen Receptor) can be effectively reduced; the continuity and safety of CAR-T (Chimeric Antigen Receptor T-cell) in vivo can be enhanced.

Systems and methods have been developed for large-scale propagation and differentiation of populations of neurons and glia from neural precursor cells derived from postnatal brain. Under culture conditions containing pituitary extract and mitogenic factors, cells derived from neural stem cells can be attached to a substrate, maintained and serially passaged in culture. Upon removal of mitogenic factors, clusters of neural progenitor cells can be induced that co-express markers of neural stem cells and immature neurons. Unlimited numbers of cells at characterized stages of neurogenesis can be produced. Upon maturation, neuronal cells extend processes and differentiate into mature neuronal phenotypes capable of generating action potentials.

The present invention provides compositions and methods for regulating fertility in mammals. In general, the invention relates to a novel protein produced by oocytes named JY-1, and nucleic acids encoding the JY-1 protein, for controlling folliculogenesis and early embryonic development, particularly in monoovulatory species. In particular, the present invention provides nucleic acid and amino acid sequences encoding JY-1, vectors for the expression of JY-1, host cells expressing JY-1, RNAi probes for reducing levels of JY-1 message, and antibodies to JY-1. Specifically, developing and mature oocytes express JY-1 in vivo, while granulosa cells treated in vitro with recombinant JY-1 (rJY-1) protein reduced cell proliferation while increasing progesterone synthesis and estradiol production. Further, reducing JY-1 protein in developing embryos in vitro using inhibitory siRNA constructs corresponded with arrested blastocyte maturation.

The invention provides a biological agent for effectively killing and wounding tumor cells. Human NK (natural killer) cells, mature B lymphocyte cells and CIK (cytokine-induced killer) cells are amplified through induction in vitro, and are combined according to a certain proportion, and the biological agent for effectively killing and wounding the tumor cells is provided. The biological agent with a combined tumor killing effect has the advantages of high tumor killing activity, wide tumor killing spectra and zero MHC (major histocompatibility complex) limitation.

The invention discloses a human immunocompetent cell DC-CIK cell preparation and an effective preparation method of the human immunocompetent cell DC-CIK cell preparation. The method includes the following steps: (1) isolating single mononuclear cell from the human peripheral blood; (2) inoculating the single mononuclear cell into the serum-free medium, adding IFN gamma, GM-CSF and IL-4 and culturing for 1 day; (3) adding IL-2, IL-15 and anti-CD3 monoclonal antibody and culturing for 2 days; (4) adding TNF alpha, continuously culturing for 1day and promoting the DC cell maturation; (5) adding IL-2 and IL-15, continuously culturing for 8 days and obtaining the DC-CIK cell; and (6) collecting the DC-CIK cell and preparing the cell preparation. Through the culturing program of the DC-CIK cell, the human immunocompetent cell DC-CIK cell preparation not only can shorten the cell culturing time, improve the multiplication rate and strengthen the killing activity of the DC-CIK cell on the cancer cell, but also can simplify the operating steps and facilitate the clinic popularization and application.

The invention relates to recombinant bacillus subtilis capable of synthesizing carotenoid 4,4'-diaponeurosporene with 30 carbon atoms (C30), and belongs to the biotechnology genetic engineering field. A bacillus subtilis expression plasmid pMK3-crtmn (which is capable of expressing C30 carotenoid synthases Crtm and Crtn in bacillus subtilis) containing C30 carotenoid synthase genes crtm and crtn is successfully constructed, and is successfully electro-transformed into bacillus subtilis WB800. The WB800 strain after transformation turns from the original color of white to yellow. A pigment component extracted from the recombinant WB800 is identified as 4,4'-diaponeurosporene by high performance liquid chromatography (HPLC). 4,4'-diaponeurosporene can stimulate maturation of dendritic cells, and generated cytokines (IL-6, IL-10, IL-12p70 and TNF[alpha]) have the amount increased, and moreover and have stronger ability to stimulate proliferation of T lymphocytes. With oral administration of the bacillus subtilis capable of synthesizing 4,4'-diaponeurosporene, the dextran sulphate sodium (DSS)-induced mice colitis symptoms can be significantly reduced. The bacillus subtilis capable of producing 4,4'-diaponeurosporene is expected to be developed as probiotics for prevention of colitis.

The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).

Compositions and methods are provided for enhancing the survival and promoting the maturation of mammalian oocytes, zygotes and preimplantation embryos. BDNF or BDNF agonists may be administered to an individual, or to cells in vitro, to enhance cellular maturation, embryo growth and fertilization. Accordingly, compositions comprising BDNF are herein presented for use in promoting in vivo oocyte maturation as well as for use as a component in culture media for promoting preimplantation maturation of zygotes and embryos, for instance, for use with in vitro fertilization procedures and for the production of stem cells. Additionally, compounds that interfere with the binding of BDNF to its receptor may be administered to an individual to prevent oocyte maturation, thereby acting as a contraceptive. The BNDF receptor, TrkB, and BDNF also find use in the screening and design of agonists and antagonists for use in the methods of the invention.

The invention provides mannose phosphate and salts thereof for increasing vaginal cell growth, vaginal cell maturation and vaginal moisture, as well as compositions, articles and methods for treating and preventing vaginal conditions characterized by poor vaginal cell growth, low vaginal cell differentiation and low vaginal moisture.

The invention provides a vaccine for treating mRNA-DC lung cancer and an enhanced preparation method of the vaccine. The method includes the steps of obtaining mRNA, IL-2 and IFN-gamma of a lung cancer stem cell, and transfecting the mRNA, the IL-2 and the IFN-gamma into DC to be cultivated in vitro. According to the method process, based on the technological foundation that the DC can receive and translate the external mRNA and codon has universality, the DC is stimulated through the method that antigen proteins are expressed after the mRNA of the lung cancer stem cell is guided in and replace inactivated proteins for stimulation, and the carried antigen information is more comprehensive; the defect that due to inactivation, breakage and the like of the externally-stimulated antigen proteins, the antigen information is lost can be overcome; meanwhile, the IL-2 and the IFN-gamma are transfected into the DC, then the mature induction can be started in the immune response process, the induction time in an ordinary culture medium can be greatly shortened, the cell maturation efficiency is improved, and immune responses are enhanced. The invention further provides a cytotoxic T lymphocyte obtained by co-culturing the vaccine for treating mRNA-DC lung cancer and a T lymphocyte.

The presently disclosed subject matter provides for methods and compositions for treating multiple myeloma. It relates to chimeric antigen receptors (CARs) that specifically target B cell maturation antigen (BMCA), and immunoresponsive cells comprising such CARs. The presently disclosed BMCA-specific CARs have enhanced immune-activating properties, including anti-tumor activity.

The presently disclosed subject matter provides for methods and compositions for treating multiple myeloma. It relates to chimeric antigen receptors (CARs) that specifically target B cell maturation antigen (BMCA), and immunoresponsive cells comprising such CARs. The presently disclosed BMCA-specific CARs have enhanced immune-activating properties, including anti-tumor activity.